biOasis Technologies Ord Shs V.BTI.H

RE:RE:Some Thoughts in Summary

[prophetoffactz]

",,Can this investment get any more erroded than it has ,,,it must be assumed it certainly can,,,,,it cant even be considered an investment anymore,,,,"

It's very important to draw a clear distinction between an investment and a speculation. It never was an 'investment'. It has always been a 'speculation'. It has never been in human trials let alone provided a proof of concept in humans. It has never been through Phase 1, 2, or 3 trials or reached final regulatory approval and market acceptance. xB3 could be 2 years from clinical trials with an internal product still after a decade of trying. Denali is years ahead of xB3 with Hunter and in trials. Lots of de-risking ahead hopefully; maybe even with Chiesi but we have no visibility into that. I don't know what Hunter data BTI is presenting in Q2 of next year. Maybe there is improvement to address compeition ahead of xB3 as Denaili and behind xB3 such as gene-therapy or potential functional cures. There is competition on all sides. 

"Now on life support at .05 cents it becomes at the most a tax loss instrument now or down the road."

Armistice Capital, likely because of Ladenberg Thalmann, has agreed to US$10 million in funding that can turn to US$20 million with warrant exercise which Biodexa's CEO believes can be triggered based on expected events. What could the market cap of Biodexa be with US$20 million cash to reach hard milestones on Biodexa's clinical trial or clinical trial ready programs addressing $12 billion with US$20 million to spend? What could licensing deals with the world's largest healthcare company(J&J) in 2023 be worth on xB3 and Q-Sphera if in 2023 the platforms are validated and an expansive pipeline can be financed in future years by Biodexa's lead clinical assets? Biodexa's lead asset for glioblastoma targets a $5 billion market providing great strength to the company and supportng a pipeline. What could the market cap of a $5 billion opportunity be worth as it is de-risked and hits the market? What could partnership deals on xB3 and Q-Sphera be worth given Biodexa's potential strength next year through clinical milestones. Could Biodexa be positioned to accelerate xB3 and Q-Sphera deals next year given its profile? There is a lot of speculation with this opportunity but a big and bold move is needed to escape the current crisis in biotech. There is a lot of dilution with the deal but it comes with a lot of upside and cash.